InMed Pharmaceuticals (INM) Interest & Investment Income (2019 - 2026)
InMed Pharmaceuticals' (INM) quarterly Interest & Investment Income came in at $47770.0 in Q1 2026, up 188.38% year-on-year from $16565.0 in Q1 2025, and down 35.77% quarter-over-quarter from $74379.0 in Q4 2025.
InMed Pharmaceuticals (INM) Interest & Investment Income (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $47770.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 188.38% year-over-year to $47770.0 in Q1 2026; TTM through Mar 2026 was $267601.0, a 28.76% increase from a year earlier, with the FY2025 full-year figure at $155882.0, down 70.47% from the prior year.
- Interest & Investment Income eased to $47770.0 in Q1 2026 per INM's latest filing, from $74379.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $166760.0 in Q4 2023 and bottomed at $16565.0 in Q1 2025.
- The 5-year median for Interest & Investment Income is $74379.0 (2025), against an average of $85694.2.
- Across the five-year window, Interest & Investment Income jumped 1310.0% in 2022 and sank 86.36% in 2025, its largest moves.
- Year by year, Interest & Investment Income stood at $115797.0 in 2022, then jumped by 44.01% to $166760.0 in 2023, then tumbled by 81.69% to $30536.0 in 2024, then surged by 143.58% to $74379.0 in 2025, then tumbled by 35.77% to $47770.0 in 2026.
- Per Business Quant, the three latest INM Interest & Investment Income figures stand at $47770.0 (Q1 2026), $74379.0 (Q4 2025), and $93765.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | InMed Pharmaceuticals | 6.80 Mn | 1.56 Mn | - | 47,770.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47,770.00 |
| Dec 31, 2025 | 74,379.00 |
| Sep 30, 2025 | 93,765.00 |
| Jun 30, 2025 | 51,687.00 |
| Mar 31, 2025 | 16,565.00 |
| Dec 31, 2024 | 30,536.00 |
| Sep 30, 2024 | 57,094.00 |
| Jun 30, 2024 | 103,640.00 |
| Mar 31, 2024 | 121,458.00 |
| Dec 31, 2023 | 166,760.00 |
| Sep 30, 2023 | 136,043.00 |
| Jun 30, 2023 | 148,559.00 |
| Mar 31, 2023 | 155,497.00 |
| Dec 31, 2022 | 115,797.00 |
| Sep 30, 2022 | 72,587.00 |
| Jun 30, 2022 | 33,701.00 |
| Mar 31, 2022 | 30,964.00 |
| Dec 31, 2021 | 26,277.00 |
| Sep 30, 2021 | 5,148.00 |
| Jun 30, 2021 | 4,825.00 |